People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cardurion Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $431.7M | $2.8B | 2021 |
| Areteia Therapeutics, Inc. | — | Biotechnology | Series D+ | $360.0M | $7.8B | 2022 |
| Solid Biosciences Inc. | — | Pharmaceuticals | Series C | $109.2M | $139.2M | 2020 |
Adam Koppel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adam Koppel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Edward Mathers | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Daniel Lynch | 1 | 7 |
| Adam Stone | 1 | 5 |
| Ian Smith | 1 | 4 |
| Emma Reeve | 1 | 4 |
| Keith Gottesdiener | 1 | 4 |
| Rajeev Shah | 1 | 4 |
| Matthew Arnold | 1 | 4 |
| Stephen E. Butts | 1 | 4 |
| Martin Freed | 1 | 3 |
| Evan Rachlin | 1 | 3 |
| Lynne Sullivan | 1 | 3 |
| Kenneth Novack | 1 | 3 |
| Michael E. Bozik | 1 | 3 |
| Peter Lawrence | 1 | 3 |
| Ilan Ganot | 1 | 3 |
| Paul Berns | 1 | 3 |
| Nicholas Downing | 1 | 2 |
| Ian Read | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.